FDA approved the protocol update for the BACKBEAT study, which utilizes Astra pacemakers.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved the protocol update for the BACKBEAT study, which utilizes Astra pacemakers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- The FDA received information on June 27, 2025, regarding regulatory approval to streamline patient monitoring for a product involving Bristol-Myers Squibb.
Coverage
Newest first; wire copies grouped- GlobeNewswireOrchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility FDA-approved protocol update significantly expands patient